<DOC>
	<DOCNO>NCT00162123</DOCNO>
	<brief_summary>The purpose study evaluate continue use ipilimumab patient reinduction time disease progression continue maintenance treatment . In addition , study continue follow patient take ipilimumab , eligible maintenance reinduction therapy .</brief_summary>
	<brief_title>A Companion Study Patients Enrolled Prior/Parent Ipilimumab Studies</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Inclusion Criteria Diagnosis advance melanoma Prior treatment prespecified prior/parent ipilimumab study Men woman 18 year age old First Reinduction : No unacceptable toxicity ( except select reversible immunerelated adverse event ) require ipilimumab discontinuation Had experience document progressive disease expand clinical benefit Extended Maintenance Received ipilimumab dose parent study Achieved expand clinical benefit time entry current study Followup : Received ipilimumab dose close parent study Deemed ineligible reinduction extend maintenance treatment refuse treatment reinduction extend maintenance time screen current study , consent followup Key Exclusion Criteria Prior treatment CD137 agonist cytotoxic Tlymphocyte antigen 4 inhibitor agonist , ipilimumab Primary ocular mucosal melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ipilimumab</keyword>
	<keyword>previously treat</keyword>
</DOC>